endometriosis
Conditions
Interventions
Have the desire of fertility A:GnRHa is used in preoperation as well as in postop
Have the desire of fertility B:GnRHa is used in postoperation
Have the desire of fertility C:GnRHa is used in preoperation
Have the desire of fertility D:No medicine is used either in operration or postop
Have no desire of fertility D:Oral contraceptive is used in postoperation
Have no desire of fertility A :GnRHa is used in preoperation as well as in postop
Have no desire of fertility B:GnRHa is used in postoperation
Have no desire of fertility C:GnRHa is used in preoperation
Sponsors
Beijing Obstetrics and Gynecology Hospital, Capital Micedal University
Eligibility
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. During 2014 and 2016, the patient comes to our hospital owing to adnexal masses. 2. The patient complained of secondary dysmenorrhea or sexual pain; 3. The uterine activity is weak, uterosacral ligaments has touch pain, and the diameters of adnexal masses are more than 3cm by bimanual examination and vagino-recto-abdominal examination; 4. The B-ultrasound report: non pure cystic mass of the ovary, whose diameter bigger than 3cm, has dense fine dotted echoes inside. 5. The disease is confirmed to be pelvic endometriosis by the pathology department after operation, and diagnosed with stage III-IV, according to the "Correction of endometriosis staging method (R - AFS) 1985" of the American Fertility Association; 6. The patient who is ready for follow-up; 7. Initial diagnosis & initial patient; 8.The patient who is volunteered to sign the Informed consent.
Exclusion criteria
Exclusion criteria: 1. The patients who have chronic disease history of hypertension, diabetes, cancer, and etc.; 2. The patients who have a history of taking tumor type of drugs; 3. The patients who had taken hormone therapies 6 months before the diagnosis; 4. The patients who have serious heart, liver, kidney and other important organs' diseases or blood and endocrine system diseases; 5. The level of serum CA125 more than 300U/ml; 6. The patients who have abnormal sexual organs' hemorrhage without decisive diagnosis; 7. The patients who have mental diseases or reasons that cannot cooperate with the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ovarian reserve capacity;pregnancy outcome;The level of pain;Interval of recurrence; | — |
Countries
China
Contacts
Public ContactWei Wei
Outcome results
None listed